Literature DB >> 3707050

Antitumour effect of benzylidene-glucose (BG) in rats with chemically induced hepatocellular carcinoma.

E O Pettersen, P E Schwarze, J M Dornish, J M Nesland.   

Abstract

The effect of 4,6-benzylidene-D-glucose (BG) on chemically induced primary hepatocellular carcinomas in rats was tested after daily single injections of 85 mg per kg body weight into the aorta through a canula implanted through the right carotid artery. Treatment started immediately following a biopsy confirming the diagnosis and continued over a period of 7 to 10 days. One day after the final injection the liver was removed and the animals sacrificed. Histological examination of the samples taken before and after treatment of the same animals indicated an extensive tumour necrosis after treatment. Complete or nearly complete tumour necrosis was found in 3 of 7 animals while no effect of treatment was found in only 1 animal. HPLC-chromatograms of BG indicated that the compound is metabolised within 1 h. A metabolite may possibly be the active component.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3707050

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  In vivo and in vitro pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats.

Authors:  J M Dornish; R O Larsen; P E Schwarze; B Børretzen; E O Pettersen
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

Review 2.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

3.  The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-D-glucose in mice and rats.

Authors:  C B Dunsaed; J M Dornish; E O Pettersen
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  4, 6-0-benzylidene-D-glucopyranose (BG) in the treatment of solid malignant tumours, an extended phase I study.

Authors:  T Tatsumura; M Tsujimoto; S Koyama; T Furuno; Y Komori; H Sato; K Yamamoto; M Kitagawa; S Kagamimori
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

5.  Tumour necrotisation in nude mice xenografts by the reversible protein synthesis inhibitor zilascorb(2H).

Authors:  E O Pettersen; R O Larsen; J M Dornish; B Børretzen; M E Juul; T E Aastveit; J M Nesland; E K Rofstad; R Oftebro
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.